ARR-15896
ARR-15896
ARR-15896 is a novel pharmacological compound currently under investigation for its potential therapeutic applications in the treatment of neurodegenerative diseases. This article provides a comprehensive overview of ARR-15896, including its chemical properties, mechanism of action, clinical trials, and potential implications in medicine.
Chemical Properties[edit | edit source]
ARR-15896 is a synthetic small molecule with a molecular weight of 350.45 g/mol. It is characterized by its high solubility in aqueous solutions and stability under physiological conditions. The compound is structurally related to other neuroprotective agents, featuring a unique arrangement of functional groups that contribute to its activity.
Mechanism of Action[edit | edit source]
ARR-15896 functions primarily as a selective agonist of the nicotinic acetylcholine receptors (nAChRs), specifically targeting the α7 subtype. By binding to these receptors, ARR-15896 enhances cholinergic neurotransmission, which is believed to play a crucial role in cognitive processes and neuroprotection. Additionally, ARR-15896 exhibits anti-inflammatory properties by modulating the release of pro-inflammatory cytokines in the central nervous system.
Clinical Trials[edit | edit source]
ARR-15896 is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with Alzheimer's disease. Preliminary results have shown promising improvements in cognitive function and a favorable safety profile. Further studies are needed to confirm these findings and to explore the potential of ARR-15896 in other neurodegenerative conditions such as Parkinson's disease and Multiple sclerosis.
Potential Implications in Medicine[edit | edit source]
The development of ARR-15896 represents a significant advancement in the field of neuropharmacology. If proven effective, it could offer a new therapeutic option for patients suffering from debilitating neurodegenerative diseases. Its dual action as a cognitive enhancer and anti-inflammatory agent makes it a particularly attractive candidate for comprehensive disease management.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
